Phase IIa trial of ARC 1905 and E 10030 in combination with anti-vascular endothelial growth factor (VEGF) therapy for the treatment of anti-VEGF resistant wet age-related macular degeneration

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Jul 2019

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Avacincaptad pegol (Primary) ; Pegpleranib (Primary) ; Vascular endothelial growth factors inhibitors
Indications Wet age-related macular degeneration
Focus Therapeutic Use

26 Jul 2017 According to an OphthoTech Corporation media release, due to a new study design and updated enrollment criteria, the Company will cease enrollment in this study and initiate a new Phase 2a clinical trial.
27 Jan 2016 Status changed from planning to recruiting, according to an OphthoTech Corporation media release.
28 Apr 2014 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com